Trusted health care advisor providing business-aware advice

Theresa DeAngelis provides compliance guidance, fraud and abuse counseling, and representation in connection with government investigations, enforcement actions and litigation. She applies her depth of experience to a wide range of health care clients, including:

• Pharmaceutical and medical device manufacturers
• Pharmacy benefit managers
• Retail, specialty, long-term care and other "closed door" pharmacies
• Wholesale distributors of drugs and medical devices
• Hospitals
• Clinical laboratories

Theresa assists her clients in navigating compliance with the Controlled Substances Act and Medicare, Medicaid and state law requirements. She counsels on fraud and abuse issues, including matters arising under the False Claims Act (FCA), the Anti-Kickback Statute, the Stark Law, the Eliminating Kickbacks in Recovery Act (EKRA), and federal and state health care reimbursement.

Before joining Quarles, Theresa represented qui tam relators in litigation under the FCA in health care fraud and retaliation matters, and whistleblowers alleging violations of the federal securities laws, including the Foreign Corrupt Practices Act, under the U.S. Securities and Exchange Commission's whistleblower program.

Theresa leverages this experience in government investigations and FCA litigation to provide holistic counseling to clients at every stage of an enforcement action.  

Bar Admissions

• District of Columbia
• Pennsylvania

Education

• Penn State Dickinson Law (J.D., 2018)

• Pennsylvania State University (M.H.A., 2018)

• Pennsylvania State University (B.S., 2014)

• "Arizona Law Update 2021-2022"
• CMS Proposed Rule to Delay Effective Date of Amended Regulatory Definitions under the Medicaid Drug Rebate Program
• Healthcare Business Today Article by Kirti Reddy, Theresa DeAngelis Addresses Benefits of Documenting Medical Necessity for Health Care Services
• Kirti Reddy and Theresa DeAngelis Author New York Law Journal Article on Evolving State Changes Guiding Medicaid Overpayment Self-Disclosure
• Massachusetts Law Permitting Pharmacies and Pharmaceutical Manufacturers to Offer Drug Discounts to Consumers Extended to January 1, 2026
• Rhode Island: Summary of Fraud and Abuse Statutes and Regulations
• Supreme Court to Review the Objective Scienter Standard Under the False Claims Act in U&C Drug Pricing Suits
• The Mifepristone Battle Enters a New Phase